MedTrace Logo

Effect of Indacaterol Maleate in Chronic Obstructive Pulmonary Disease (COPD) on Lung Volume and Related Dyspnea

NCT01377051 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-10-29

No results posted yet for this study

Summary

The purpose of this study is to determine whether indacaterol maleate 300 micrograms (mcg) is effective in the acute treatment of COPD and in particular on reducing lung hyperinflation and dynamic volumes.

Conditions

Interventions

DRUG

Indacaterol maleate

Dry powered, 300 mcg, only one inhalation with 24 hours duration

DRUG

Placebo

Dry powered, same to study drug, only one inhalation

Sponsors & Collaborators

  • Fondazione Salvatore Maugeri

    collaborator OTHER

  • University of Milan

    lead OTHER

Principal Investigators

  • Pierachille Santus, MD, PhD · Università degli Studi di Milano-Pneumologia Riabilitativa- Fondazione Maugeri-Istituto Scientifico di Milano-IRCCS - [email protected]

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2011-08-31
Completion
2011-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01377051 on ClinicalTrials.gov